trending Market Intelligence /marketintelligence/en/news-insights/trending/py3khab5-sob6laq5juxva2 content esgSubNav
In This List

Indivior secures license for C4X Discovery's therapies for substance addiction

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Indivior secures license for C4X Discovery's therapies for substance addiction

Indivior PLC agreed to buy exclusive global rights to develop and commercialize U.K.-based C4X Discovery Holdings PLC's potential treatment for substance addiction.

Under the agreement, the Richmond, Va.-based Indivior would pay C4X $10 million upfront, with potential milestone payments of up to $284 million.

The deal involves C4X Discovery's drugs, including lead candidate C4X3256, that block the orexin-1 protein in the body to decrease addiction related to opioids, alcohol and psychomotor stimulants such as cocaine.